SV Health Investors’s X4 Pharmaceuticals XFOR Stock Holding History

SV Health Investors’s Portfolio XFOR Stock Details XFOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$532K	Hold	10,383	–	–	1.65%	3
2022 Q2	$300K	Hold	10,383	–	–	0.68%	4
2022 Q1	$545K	Hold	10,383	–	–	0.66%	4
2021 Q4	$713K	Hold	10,383	–	–	0.46%	5
2021 Q3	$1.65M	Hold	10,383	–	–	0.81%	7
2021 Q2	$2.02M	Hold	10,383	–	–	0.88%	6
2021 Q1	$2.68M	Hold	10,383	–	–	1%	7
2020 Q4	$2M	Hold	10,383	–	–	0.97%	8
2020 Q3	$2.11M	Hold	10,383	–	–	1.07%	8
2020 Q2	$2.9M	Hold	10,383	–	–	2.01%	7
2020 Q1	$3.12M	Hold	10,383	–	–	2.61%	7
2019 Q4	$3.33M	Hold	10,383	–	–	2.02%	7
2019 Q3	$3.96M	Hold	10,383	–	–	2.78%	8
2019 Q2	$4.67M	Hold	10,383	–	–	3.14%	7
2019 Q1	$5.42M	Hold	10,383	–	–	3.18%	6
2018 Q4	$4.34M	Hold	10,383	–	–	2.67%	6
2018 Q3	$3.03M	Hold	10,383	–	–	0.89%	7
2018 Q2	$6.79M	Hold	10,383	–	–	3.12%	6
2018 Q1	$42.8M	Hold	10,383	–	–	32.08%	1
2017 Q4	$23.8M	Buy	+10,383	New	+$26.3M	12.6%	4

Other funds holding XFOR

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

TLP

Tri Locum Partners New York $813M AUM 101.01% 1-Year Est. Return

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

PHP

Parkman Healthcare Partners Stamford, Connecticut $977M AUM 110.37% 1-Year Est. Return

SV Health Investors's XFOR Position: Q3 2022 in Review

SV Health Investors held its X4 Pharmaceuticals (XFOR) position steady in Q3 2022 at 10,383 shares worth $532K. The position accounts for 1.65% of the portfolio, ranked #3.

SV Health Investors first reported a position in XFOR in Q4 2017 and has held it in 20 quarters since. The position peaked at $42.8M in Q1 2018. 56 funds tracked by Wall St. Rank hold XFOR as of Q3 2022.

SV Health Investors held 10,383 shares of X4 Pharmaceuticals worth $532K as of Q3 2022.
SV Health Investors left its X4 Pharmaceuticals share count unchanged in Q3 2022.
X4 Pharmaceuticals made up 1.65% of SV Health Investors's portfolio in Q3 2022, its #3 holding.
SV Health Investors first reported a position in X4 Pharmaceuticals in Q4 2017 and has held it in 20 quarters since.
SV Health Investors's X4 Pharmaceuticals position peaked at $42.8M in Q1 2018.
56 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q3 2022.

Based on SV Health Investors's 13F filing for Q3 2022, filed 7 Nov 2022.